BCL2 and B-cell chronic lymphocytic leukemia: In addition, splicing modulation with the pladienolide B derivative E7107 sensitizes CLL cells to venetoclax therapy by reducing their dependency on MCL1 and increasing their dependence on BCL2 (Hacken et al, 2018).